June 7, 2016

PharmaCyte Biotech to Present Cancer and Diabetes Therapies at 2016 BIO International Convention

SILVER SPRING, Md., June 07, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte's therapies for cancer and diabetes at this year's BIO International Convention (BIO). Meetings have been scheduled with big pharma potential investors, strategic partners and the media. The 2016 BIO International Convention is being held at the Moscone Center in San Francisco June 6-9, 2016.

PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, stated, "We are excited to attend this year's BIO right on the heels of an extraordinarily productive working session at ASCO with a host of renowned oncologists who were introduced to our Cell-in-a-Box® therapy for pancreatic cancer. Their input has resulted in further refinement of the design of our Phase 2b clinical trial, which we'll explain to those we meet with at BIO. We have attracted considerable interest of late in the biotech sector and plan to capitalize on this while here in San Francisco. We have a golden opportunity for the world to learn more about PharmaCyte's novel therapies for cancer and diabetes than ever before, and to learn why we believe they will have such a positive impact on patients who suffer from these dreadful diseases."

BIO is the world's largest biotechnology gathering. Over 40,000 people are expected to attend this year. BIO features 1,800 exhibitors and 55 regional and international pavilions, with 8 specialized product focus zones. BIO attracts over 15,000 biotechnology and pharma leaders who come together for intensive networking to discover new opportunities and promising partnerships. The event covers a wide spectrum of life science applications, such as cell therapy and drug discovery. BIO allows companies like PharmaCyte the opportunity to interact with influential decision makers and high-level executives that come to BIO to discover new therapies in the biotechnology sector, evaluate emerging technologies and form new partnerships.

About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte's treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body

(ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.

In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.

Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend", "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.

More information about PharmaCyte can be found atwww.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com

PHARMACYTE BIOTECH

Source: PharmaCyte Biotech, Inc.